<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495285</url>
  </required_header>
  <id_info>
    <org_study_id>HC-O-H-1406</org_study_id>
    <nct_id>NCT02495285</nct_id>
  </id_info>
  <brief_title>Gelatines in Pediatric PatientS</brief_title>
  <acronym>GPS</acronym>
  <official_title>Infusion of Gelatine Solutions in Pediatric Patients Aged up to 12 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of volume replacement is to compensate a reduction in the intravascular volume e.g.
      during surgery and to counteract hypovolemia in order to maintain hemodynamics and vital
      functions. So far, there is only few data on the safety and efficacy of the products under
      investigation in children.

      The primary aim of this non-interventional observational study (NIS) is to collect further
      data of gelatine solutions in a large pediatric population during routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dosing of the products during surgery</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potentia hydrogenii</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>g/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum prolin</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>µmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of (Serious) adverse events / reactions</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up assessed by number of participants with post-operative complications</measure>
    <time_frame>At discharge from the hospital or in-hospital 3 months after start of gelatine infusion, whatever occurs first.</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Treatment of Hypovolemia and Shock</condition>
  <arm_group>
    <arm_group_label>Gelofusine 4%</arm_group_label>
    <description>Children age ≤ 12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelaspan 4%</arm_group_label>
    <description>Children age ≤ 12 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gelofusine 4%</intervention_name>
    <arm_group_label>Gelofusine 4%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gelaspan 4%</intervention_name>
    <arm_group_label>Gelaspan 4%</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        children
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion:

          -  Age ≤ 12 years

          -  American Society of Anesthesiologists (ASA) risk score: ≤ III

          -  Peri-operative infusion of gelatine solutions

          -  Informed consent and/or data protection declaration signed by parents/legal guardians
             (according to local requirements)

        Exclusion:

          -  Inclusion in another investigational study in the field of volume replacement which
             could interfere with the routine clinical practice regarding the administration of the
             gelatine solutions

          -  In addition contraindications as outlined in the valid local Summaries of Product
             Characteristics (SmPCs) have to be considered.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sümpelmann, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Hochschule Hannover (MHH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>+49-5661-71-0</phone>
    <email>studies@bbraun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Auf der Bult</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Eich, Prof. Dr. med.</last_name>
      <phone>+49 511 8115</phone>
      <phone_ext>6611</phone_ext>
      <email>eich@hka.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Pädiatrische Kardiologie und Intensivmedizin</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Sümpelmann, Prof. Dr. med.</last_name>
      <phone>+49 5 11532</phone>
      <phone_ext>9080</phone_ext>
      <email>suempelmann.robert@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Robert Sümpelmann, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Hallerwiese/Cnopf´sche Kinderklinik</name>
      <address>
        <city>Nuernberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Becke, Dr. med.</last_name>
      <phone>+49-911-3340</phone>
      <phone_ext>4900</phone_ext>
      <email>Karin.Becke@diakonieneuendettelsau.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Olgahospital und Frauenklinik</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz-Josef Kretz, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Universitaria G. Rodolico -Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>I-95100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marinella Astuto, Prof. Dr.</last_name>
      <email>astmar@tiscali.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale dei Bambini Vittore Buzzi</name>
      <address>
        <city>Milano</city>
        <zip>I-20154</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Camporesi, Dr.</last_name>
      <email>anna.camporesi@asst-fbf-sacco.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS FT</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Murphy, Dr.</last_name>
      <email>Peter.Murphy@alderhey.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>July 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric patients gelatine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polygeline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

